Teladoc (NYSE:TDOC) – Equities research analysts at Cantor Fitzgerald lifted their FY2019 earnings per share (EPS) estimates for shares of Teladoc in a report issued on Tuesday, May 22nd. Cantor Fitzgerald analyst S. Halper now forecasts that the health services provider will post earnings per share of ($0.40) for the year, up from their prior forecast of ($0.41). Cantor Fitzgerald currently has a “Hold” rating and a $35.00 target price on the stock.
Teladoc (NYSE:TDOC) last released its quarterly earnings results on Tuesday, May 1st. The health services provider reported ($0.39) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.43) by $0.04. The company had revenue of $89.64 million for the quarter, compared to analysts’ expectations of $86.77 million. Teladoc had a negative return on equity of 20.40% and a negative net margin of 41.06%. The business’s quarterly revenue was up 109.0% compared to the same quarter last year. During the same period in the previous year, the business posted ($0.30) earnings per share.
Several other research firms have also recently weighed in on TDOC. SunTrust Banks boosted their price target on Teladoc to $48.00 and gave the stock a “positive” rating in a report on Wednesday, May 2nd. Canaccord Genuity lifted their price objective on Teladoc from $42.00 to $43.00 and gave the stock a “buy” rating in a research note on Wednesday, January 31st. Chardan Capital reaffirmed a “buy” rating and issued a $47.00 price objective (down from $48.00) on shares of Teladoc in a research note on Wednesday, February 28th. KeyCorp reaffirmed an “overweight” rating and issued a $50.00 price objective (up from $41.00) on shares of Teladoc in a research note on Thursday, March 15th. Finally, ValuEngine raised Teladoc from a “sell” rating to a “hold” rating in a research note on Friday, February 2nd. One analyst has rated the stock with a sell rating, five have issued a hold rating, twelve have assigned a buy rating and one has issued a strong buy rating to the company. The company has a consensus rating of “Buy” and an average target price of $42.67.
NYSE:TDOC opened at $50.70 on Thursday. The stock has a market cap of $3.11 billion, a PE ratio of -30.73 and a beta of 0.35. The company has a current ratio of 4.15, a quick ratio of 4.15 and a debt-to-equity ratio of 0.38. Teladoc has a 1-year low of $27.30 and a 1-year high of $51.45.
A number of institutional investors and hedge funds have recently modified their holdings of the business. SG Americas Securities LLC bought a new stake in shares of Teladoc during the fourth quarter valued at approximately $101,000. We Are One Seven LLC increased its holdings in shares of Teladoc by 241.1% during the first quarter. We Are One Seven LLC now owns 2,845 shares of the health services provider’s stock valued at $115,000 after acquiring an additional 2,011 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank increased its holdings in shares of Teladoc by 68.8% during the first quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,874 shares of the health services provider’s stock valued at $116,000 after acquiring an additional 1,171 shares in the last quarter. Rockefeller Capital Management L.P. bought a new stake in shares of Teladoc during the first quarter valued at approximately $154,000. Finally, Montag A & Associates Inc. bought a new stake in shares of Teladoc during the fourth quarter valued at approximately $200,000.
In other Teladoc news, insider Adam C. Vandervoort sold 27,809 shares of the business’s stock in a transaction that occurred on Friday, March 2nd. The stock was sold at an average price of $38.62, for a total value of $1,073,983.58. Following the transaction, the insider now directly owns 19,338 shares of the company’s stock, valued at $746,833.56. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, CFO Mark Hirschhorn sold 100,000 shares of the business’s stock in a transaction that occurred on Wednesday, February 28th. The shares were sold at an average price of $39.60, for a total value of $3,960,000.00. Following the completion of the transaction, the chief financial officer now directly owns 98,960 shares in the company, valued at $3,918,816. The disclosure for this sale can be found here. Over the last three months, insiders sold 483,954 shares of company stock worth $19,960,682. Insiders own 3.95% of the company’s stock.
Teladoc, Inc provides telehealth services worldwide. It offers a portfolio of services and solutions covering 450 medical subspecialties, such as flu and upper respiratory infections, cancer, and congestive heart failure. The company provides its services through mobile devices, the Internet, video, and phone.
Receive News & Ratings for Teladoc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teladoc and related companies with MarketBeat.com's FREE daily email newsletter.